S-1/A: Invizyne Technologies Files for IPO, Aiming to Revolutionize Biomanufacturing

Invizyne Technologies seeks to go public, planning to use proceeds to expand its SimplePath biomanufacturing platform for pharmaceuticals and biofuels.

Summary

• Invizyne Technologies, a pre-revenue, development-stage company, has filed for an IPO to raise capital for its SimplePath biomanufacturing platform.
• The company aims to transform natural resources into chemicals for pharmaceuticals, fuels, and food additives.
• Invizyne's SimplePath platform uses enzyme-based systems as an alternative to chemical synthesis, natural extraction, and synthetic biology.
• The company is offering 4,300,000 shares of common stock at $4.00 per share, aiming to raise $17.2 million.
• MDB Capital Holdings, LLC, the majority holder of Invizyne's common stock, is offering 8,027,538 shares in the offering.
• The company intends to list its common stock on The Nasdaq Capital Market under the symbol IZTC.
• Net proceeds from the offering are estimated to be approximately $15.47 million, which will be used to expand production capabilities, increase staff, expand business development, sales and marketing efforts, expand research and development and technology platform and add to working capital.

Sentiment

Score: 5

Explanation: The document presents a mix of promising technology and significant financial risks. The company's innovative approach to biomanufacturing is a positive, but its pre-revenue status and need for additional funding create uncertainty.

Positives

• The SimplePath platform has the potential to be more efficient, less environmentally damaging, and more cost-effective than traditional methods.
• The company has successfully demonstrated the feasibility of manufacturing chemicals using SimplePath processes in a laboratory setting.
• The company has received US government grants totaling $12,739,318 since inception.
• The company's primary commercialization strategy is to collaborate with third parties to engage in aspects of product research, testing, marketing, manufacturing, and product distribution.

Negatives

• Invizyne is a pre-revenue, development-stage company with a limited operating history.
• The company has incurred losses to date and may not be able to sustain its operations or become profitable.
• The company anticipates needing additional funding in the future.
• The company is highly dependent on retaining its scientific staff and being able to hire additional scientific and related managerial staff.
• Laboratory conditions may not be reproduced in a commercial setting.
• The company's business is highly dependent on a small number of products.
• The company does not have any sales, marketing, manufacturing and distribution capabilities or arrangements, and will need to create these as it moves towards commercialization of its products.

Risks

• The synthetic biological platform being developed by the Company may not be able to develop a pipeline of commercial products.
• There may be regulatory hurdles that will have to be satisfied before the bio-synthesized compounds can be marketed and commercially used.
• The company's processes rely on the need for purified enzymes and co-factors, which are energy molecules, such as ATP or NADPH.
• The company will face extensive competition from legacy processes and other companies seeking to use bio-manufacturing and enzyme pathways to develop products alternative to traditional chemicals and petroleum based products.
• If the company is unable to protect the intellectual property used in its technology platform and products, others may be able to copy its innovations.
• The company will incur increased costs as a result of operating as a public company.
• The company is an emerging growth company under the JOBS Act and the reduced disclosure requirements may make its Common Stock less attractive to investors.
• The price of the company's Common Stock may have little or no relationship to the historical sales price of its capital stock in its private placement transactions to date.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its Common Stock.
• The company may allocate the net proceeds from this offering in ways that differ from the estimates discussed in the section titled Use of Proceeds and with which you may not agree, and if the company does not use those proceeds effectively your investment could be harmed.
• You will experience immediate dilution in the book value per share of the Common Stock you purchase.

Future Outlook

The company plans to expand production capabilities, increase staff, expand business development, sales and marketing efforts, expand research and development and technology platform and add to working capital.

Industry Context

The biobased industry is expanding into sectors such as agriculture, acrylic acid products, food production and safety, cleaning products, lubricants, detergents, fertilizers and many other chemicals in common use today.

Comparison to Industry Standards

• Debut Biotech and Solugen Inc. promote the advantages of cell-free enzymatic systems over cell-based systems, but their processes appear to use simple one to two step pathways.
• Codexis, Inc. partnered with Tate&Lyle and Merck & Co., Inc. on different, highly specific projects that use multi enzyme pathways, which demonstrate that enzymatic Islatravir synthesis illustrates the potential for complex or longer enzyme cascades of the type used in some of our SimplePath systems, but their principal mission diverges from the enzymatic manufacturing of more general chemicals.
• There are many companies that focus on enzyme engineering, such as Codexis, Inc., Allozymes Pte Ltd. (Singapore), Enzymit Ltd. (Israel and US), Zymtronix Catalytic Systems, Inc., Arzeda Corp. and Quantumzyme LLP (India).
• There are other companies that develop enzyme immobilization technologies.
• There are many companies operating in the biofuels space, such as Valero Energy Corporation, ADM Corporation and Cargill Company and Gevo, Inc. and Butamax Advanced Biofuels LLC that focus on ethanol technologies.

Management Changes

Related Party Transactions

• During 2023, MDB Capital Holdings, LLC provided the financial services of its chief financial officer to the Company.
• The value of these services was determined to be $95,000, which was charged to operations.
• The amount remains unpaid as of December 31, 2023.

Stakeholder Impact

• New investors will experience immediate dilution in the book value per share of the Common Stock they purchase.
• Existing shareholders' ownership interest will be diluted if the company raises additional funds by selling equity based securities.
• The company's success depends on retaining its current scientific and other staff and being able to hire additional employees with specialized backgrounds as needed.

Next Steps

• The company intends to use the net proceeds from this offering to expand the production capabilities of the Company, including capital expenditures.
• The company intends to use the net proceeds from this offering to increase our staff.
• The company intends to use the net proceeds from this offering to expand our business development, sales and marketing efforts.
• The company intends to use the net proceeds from this offering to expand our research and development and technology platform.
• The company intends to use the net proceeds from this offering to add to our working capital.

Key Dates

Keywords

biomanufacturing, SimplePath, IPO, enzyme, cannabinoids, isobutanol, biofuels, synthetic biology, MDB Capital Holdings, biocatalysis